New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Key Highlights
- ➤Week 2 biomarker changes significantly correlated with Week 16 EASI improvement (p<0.001)
- ➤Week 16 EASI reduction reached 64% in the 100-patient molecular cohort
- ➤59 patients received planned Phase 3 dose of 24 µg/kg every two weeks
- ➤Rezpegaldesleukin (NKTR) significantly normalized Th1, Th2, Th17, and JAK-STAT pathways
- ➤Nektar (NKTR) plans to advance rezpegaldesleukin through Phase 3
Expert Statements
Emma Guttman-Yassky, Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai
“More than half of adults with atopic dermatitis report inadequately controlled disease despite treatment with currently available biologics that target type 2 inflammation, underscoring the complexity of treating this heterogeneous disease and leaving a major unmet need for a novel approach to immune modulation”
Emma Guttman-Yassky, Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai
“These data show that rezpegaldesleukin's novel approach to regulatory Tcell stimulation has the potential to treat patients with heterogeneous disease in atopic dermatitis and other autoimmune disease settings.”
Emma Guttman-Yassky, Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai
“Within 2 weeks of treatment, we observed significant systemic and cutaneous normalization across multiple disease associated pathways. Importantly, these early molecular changes correlated with clinical outcomes at Week 16 only in the rezpegaldesleukin-treated patients, providing a meaningful link between the biological activity of rezpegaldesleukin and the subsequent clinical benefit.”
Jonathan Zalevsky, Chief Research and Development Officer at Nektar Therapeutics
“These data further solidify rezpegaldesleukin's potential to restore immune balance by stimulating regulatory Tcells rather than suppressing a single inflammatory pathway, highlighting its promise as a pipeline in a product,”
Jonathan Zalevsky, Chief Research and Development Officer at Nektar Therapeutics
“This latest analysis highlights both the breadth and speed of the molecular response, strengthening our confidence in rezpegaldesleukin's differentiated mechanism of action as we advance the program through Phase 3.”
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis PR Newswire
Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response
Get started
Create a free account to read the full story.